Welcome to Vimpat. This site is screen reader friendly.

Skip to content Skip to main navigation Skip to footer navigation

* Indicates a required field

First Name:*

Last Name:*

E-mail Address:*

Confirm E-mail Address:*

Specialty:*

Address 1:

Address 2:

City:

State:

ZIP Code:

By providing this information, I give UCB, Inc. permission to send me information about epilepsy medication and other similar products from UCB, Inc. and its business partners. I understand that UCB, Inc. or its business partners will not sell or transfer my name, address, e-mail address, or any other information to any other party for their own marketing use. I can remove myself from the mailing list at any time by clicking Unsubscribe on the e-Newsletters that I will receive. Please review the privacy policy of UCB, Inc.

Indication

Vimpat^® (lacosamide) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients.

Important Safety Information

Warnings and Precautions

AEDs increase the risk of suicidal behavior and ideation. Patients taking Vimpat should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Patients should be advised that Vimpat may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In patients with seizure disorders, Vimpat should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with Vimpat should be discontinued.

Vimpat oral solution contains aspartame, a source of phenylalanine. A 200-mg dose of Vimpat oral solution (equivalent to 20 mL) contains 0.32 mg of phenylalanine.

Common Adverse Reactions

The most common adverse reactions occurring in ≥10 percent of Vimpat-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment. Use in severe hepatic impairment patients is not recommended.

Please see Vimpat Prescribing Information.